About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker OGN · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Aug 17, 2026NEXPLANON
ETONOGESTREL
OGN
Organon
New drug (NDA), supplement
REMS
NDA021529 ↗
Jul 6, 2026ELOCON
MOMETASONE FUROATE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019796 ↗
Letter or label ↗
Jul 6, 2026ELOCON
MOMETASONE FUROATE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019625 ↗
Letter or label ↗
Jul 6, 2026ELOCON
MOMETASONE FUROATE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019543 ↗
Letter or label ↗
May 28, 2026NEXPLANON
ETONOGESTREL
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021529 ↗
May 15, 2026Jada System (Jada-2002)OGN
Organon, LLC
Device clearance (510(k))
Traditional
K253642 ↗
Mar 19, 2026SINEMET CR
CARBIDOPA; LEVODOPA
OGN
Organon LLC
New drug (NDA), supplement
Labeling
NDA019856 ↗
Mar 19, 2026SINEMET
CARBIDOPA; LEVODOPA
OGN
Organon
New drug (NDA), supplement
Labeling
NDA017555 ↗
Mar 18, 2026PROSCAR
FINASTERIDE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020180 ↗
Feb 3, 2026FOSAMAX PLUS D
ALENDRONATE SODIUM; CHOLECALCIFEROL
OGN
Organon LLC
New drug (NDA), supplement
Labeling
NDA021762 ↗
Feb 3, 2026FOSAMAX
ALENDRONATE SODIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020560 ↗
Jan 16, 2026NEXPLANON
ETONOGESTREL
OGN
Organon
New drug (NDA), supplement
Efficacy
NDA021529 ↗
Jul 23, 2025REMERON
MIRTAZAPINE
OGN
Organon
New drug (NDA), supplement
Manufacturing (CMC)
NDA020415 ↗
Jun 20, 2025HYZAAR
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020387 ↗
Jun 20, 2025COZAAR
LOSARTAN POTASSIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020386 ↗
Jun 5, 2025DULERA
FORMOTEROL FUMARATE; MOMETASONE FUROATE
OGN
Organon LLC
New drug (NDA), supplement
Manufacturing (CMC)
NDA022518 ↗
Dec 12, 2024VTAMA
TAPINAROF
OGN
Organon LLC
New drug (NDA), supplement
Efficacy
NDA215272 ↗
Oct 28, 2024LIPTRUZET
ATORVASTATIN CALCIUM; EZETIMIBE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA200153 ↗
Letter or label ↗
Oct 28, 2024LIPTRUZET
ATORVASTATIN CALCIUM; EZETIMIBE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA200153 ↗
Letter or label ↗
Oct 28, 2024LIPTRUZET
ATORVASTATIN CALCIUM; EZETIMIBE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA200153 ↗
Letter or label ↗
Jul 8, 2024CELESTONE SOLUSPAN
BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA014602 ↗
Jun 5, 2024CELESTONE SOLUSPAN
BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA014602 ↗
Mar 28, 2024VYTORIN
EZETIMIBE; SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021687 ↗
Feb 21, 2024ZETIA
EZETIMIBE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021445 ↗
Feb 8, 2024VYTORIN
EZETIMIBE; SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021687 ↗
Letter or label ↗
Feb 8, 2024VYTORIN
EZETIMIBE; SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021687 ↗
Letter or label ↗
Feb 8, 2024VYTORIN
EZETIMIBE; SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021687 ↗
Letter or label ↗
Sep 29, 2023NEXPLANON
ETONOGESTREL
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021529 ↗
Sep 29, 2023NEXPLANON
ETONOGESTREL
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021529 ↗
Sep 29, 2023NEXPLANON
ETONOGESTREL
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021529 ↗
Aug 9, 2023ZOCOR
SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019766 ↗
Jul 20, 2023ZETIA
EZETIMIBE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021445 ↗
Mar 17, 2023HYZAAR
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020387 ↗
Mar 14, 2023ZOCOR
SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019766 ↗
Mar 6, 2023XACIATO
CLINDAMYCIN PHOSPHATE
OGN
Organon LLC
New drug (NDA), supplement
Labeling
NDA215650 ↗
Sep 6, 2022CELESTONE SOLUSPAN
BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA014602 ↗
Aug 1, 2022PROPECIA
FINASTERIDE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020788 ↗
Jun 28, 2022NASONEX
MOMETASONE FUROATE
OGN
Organon LLC
New drug (NDA), supplement
Labeling
NDA020762 ↗
May 31, 2022ZOCOR
SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019766 ↗
May 23, 2022VTAMA
TAPINAROF
OGN
Organon LLC
New drug (NDA)
Type 1 - New Molecular Entity
NDA215272 ↗
Letter or label ↗
Mar 7, 2022ZOCOR
SIMVASTATIN
OGN
Organon
New drug (NDA), supplement
Labeling
NDA019766 ↗
Dec 7, 2021XACIATO
CLINDAMYCIN PHOSPHATE
OGN
Organon LLC
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA215650 ↗
Nov 18, 2021REMERON
MIRTAZAPINE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020415 ↗
Letter or label ↗
Oct 15, 2021COZAAR
LOSARTAN POTASSIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020386 ↗
Letter or label ↗
Aug 25, 2021PROSCAR
FINASTERIDE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020180 ↗
Jun 15, 2021PROPECIA
FINASTERIDE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020788 ↗
Letter or label ↗
Jun 15, 2021PROSCAR
FINASTERIDE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020180 ↗
Letter or label ↗
Apr 13, 2021PROSCAR
FINASTERIDE
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020180 ↗
Letter or label ↗
Feb 22, 2021SINGULAIR
MONTELUKAST SODIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA021409 ↗
Letter or label ↗
Feb 22, 2021SINGULAIR
MONTELUKAST SODIUM
OGN
Organon
New drug (NDA), supplement
Labeling
NDA020830 ↗
Letter or label ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:15 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates